research use only

N-Acetyl-5-hydroxytryptamine Trk receptor agonist

Name: N-Acetyl-5-hydroxytryptamine
Brand: Selleck Chemicals
SKU: S2985
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S2985

N-Acetyl-5-hydroxytryptamine (NAS, N-Acetylserotonin, Normelatonin, O-Demethylmelatonin), a precursor of melatonin, is a potent and selective agonist of TrkB receptor.

Chemical Structure

Molecular Weight: 218.25

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S298501 DMSO]43 mg/mL]false]Ethanol]43 mg/mL]false]Water]Insoluble]false Purity: 99.93%

99.93

Related Targets	HDAC Caspase MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease Proteasome Serine Protease Secretase PCSK9 Glutaminase Acyltransferase Thrombin Cathepsin B MALT PAD PREP Neprilysin Carboxypeptidase SGK Aminopeptidase 3C-Like Protease PSMA PGDS GOT
Related Products	ANA-12 GW441756 7,8-Dihydroxyflavone GNF-5837 Selitrectinib (LOXO-195) Altiratinib LM22A-4 Anti-TrkB / NTRK2 CH7057288 Pan Trk Antibody [B9H18] Trk (pan) Antibody [N18M6] TrkC Antibody [P17E7] TrkB Antibody [N21K17] PF-06273340 LM22B-10 Phospho-TrkA (Tyr674/675)/TrkB (Tyr706/707) Antibody [K13K11] TrkB Antibody [B5D18] BDNF Antibody [E17G19] Anti-TrkA / NTRK1

Chemical Information, Storage & Stability

Molecular Weight	218.25	Formula	C₁₂H₁₄N₂O₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1210-83-9	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	NAS, N-Acetylserotonin, Normelatonin, O-Demethylmelatonin			Smiles	CC(=O)NCCC1=C[NH]C2=C1C=C(O)C=C2

Solubility

In vitro
Batch:

DMSO : 43 mg/mL (197.02 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 43 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	TrkB receptor ^[1]
References	[1] https://pubmed.ncbi.nlm.nih.gov/20133677/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06154590	Not yet recruiting	Metastatic Breast Cancer\|Tumor\|Muscle Neoplasms\|Chronic Pain	DR. DIANE CHISESI NFS. MD. PHD.\|IRB\|Paradyne Networks A Foundation	July 2024	--
NCT06322628	Not yet recruiting	Nash	Visirna Therapeutics HK Limited	April 2024	Phase 2
NCT06318169	Recruiting	Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis	89bio Inc.	March 13 2024	Phase 3
NCT05979389	Recruiting	NAFLD\|PCOS	University of California San Francisco\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	February 14 2024	Phase 1
NCT05118360	Withdrawn	Nonalcoholic Steatohepatitis (NASH)	Gannex Pharma Co. Ltd.	December 1 2023	Phase 2
NCT06215716	Recruiting	NASH With Fibrosis\|MASH With Fibrosis	Akero Therapeutics Inc	December 1 2023	Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):